FDA
-
-
-
-
-
-
-
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Adicet Bio doses first systemic sclerosis patient in phase 1 trial
-
-
-
-
-
-
-
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Adicet Bio (ACET) Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
-
-
-
-
-
-
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)
-
330,063 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

